IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results …

P Emery, E Keystone, HP Tony, A Cantagrel… - Annals of the …, 2008 - ard.bmj.com
Objectives: The phase III RADIATE study examined the efficacy and safety of tocilizumab, an
anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to …

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

JM Van Laar, D Farge, JK Sont, K Naraghi… - Jama, 2014 - jamanetwork.com
Importance High-dose immunosuppressive therapy and autologous hematopoietic stem cell
transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small …

Current state of evidence on 'off-label'therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and …

M Aringer, H Burkhardt, GR Burmester… - Lupus, 2012 - journals.sagepub.com
Systemic lupus erythematosus (SLE) can be a severe and potentially life-threatening
disease that often represents a therapeutic challenge because of its heterogeneous organ …

γδ T cells for immune therapy of patients with lymphoid malignancies

M Wilhelm, V Kunzmann, S Eckstein, P Reimer… - Blood, 2003 - ashpublications.org
There is increasing evidence that γδ T cells have potent innate antitumor activity. We
described previously that synthetic aminobisphosphonates are potent γδ T cell stimulatory …

Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritis

P Roll, A Palanichamy, C Kneitz… - … : Official Journal of the …, 2006 - Wiley Online Library
Objective Transient B cell depletion with the monoclonal anti‐CD20 antibody rituximab has
resulted in favorable clinical responses in patients with rheumatoid arthritis (RA). However …

[HTML][HTML] Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

HP Tony, G Burmester, H Schulze-Koops… - Arthritis research & …, 2011 - Springer
Introduction Evidence from a number of open-label, uncontrolled studies has suggested that
rituximab may benefit patients with autoimmune diseases who are refractory to standard-of …

Anti‐CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

P Roll, T Dörner, HP Tony - … Journal of the American College of …, 2008 - Wiley Online Library
Objective B cell depletion with the anti‐CD20 antibody rituximab has proven efficacy in
patients with rheumatoid arthritis (RA). The effects on B cell homeostasis after repeated …

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

F Braig, A Brandt, M Goebeler, HP Tony… - Blood, The Journal …, 2017 - ashpublications.org
The CD19 antigen is a promising target for immunotherapy of acute lymphoblastic leukemia
(ALL), but CD19− relapses remain a major challenge in about 10% to 20% of patients. Here …

Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised …

J Haschka, M Englbrecht, AJ Hueber… - Annals of the …, 2016 - ard.bmj.com
Objective To prospectively analyse the risk for disease relapses in patients with rheumatoid
arthritis (RA) in sustained remission, either continuing, tapering or stopping disease …

Evaluation of pannus and vascularization of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis by high‐resolution ultrasound …

M Hau, H Schultz, HP Tony, M Keberle… - … : Official Journal of …, 1999 - Wiley Online Library
Objective To evaluate the extent of intraarticular vascularization and pannus formation in
metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints of patients with …